MYC determines lineage commitment in KRAS-driven primary liver cancer development.
Cancer
Cell of origin
Hepatocellular carcinoma (HCC)
Hepatocyte
Intrahepatic cholangiocarcinoma (iCCA)
Liver
MYC
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
27
12
2022
revised:
24
02
2023
accepted:
28
02
2023
pmc-release:
01
07
2024
medline:
19
6
2023
pubmed:
12
3
2023
entrez:
11
3
2023
Statut:
ppublish
Résumé
Primary liver cancer (PLC) comprises hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), two frequent and lethal tumour types that differ regarding their tumour biology and responses to cancer therapies. Liver cells harbour a high degree of cellular plasticity and can give rise to either HCC or iCCA. However, little is known about the cell-intrinsic mechanisms directing an oncogenically transformed liver cell to either HCC or iCCA. The scope of this study was to identify cell-intrinsic factors determining lineage commitment in PLC. Cross-species transcriptomic and epigenetic profiling was applied to murine HCCs and iCCAs and to two human PLC cohorts. Integrative data analysis comprised epigenetic Landscape In Silico deletion Analysis (LISA) of transcriptomic data and Hypergeometric Optimization of Motif EnRichment (HOMER) analysis of chromatin accessibility data. Identified candidate genes were subjected to functional genetic testing in non-germline genetically engineered PLC mouse models (shRNAmir knockdown or overexpression of full-length cDNAs). Integrative bioinformatic analyses of transcriptomic and epigenetic data pinpointed the Forkhead-family transcription factors FOXA1 and FOXA2 as MYC-dependent determination factors of the HCC lineage. Conversely, the ETS family transcription factor ETS1 was identified as a determinant of the iCCA lineage, which was found to be suppressed by MYC during HCC development. Strikingly, shRNA-mediated suppression of FOXA1 and FOXA2 with concomitant ETS1 expression fully switched HCC to iCCA development in PLC mouse models. The herein reported data establish MYC as a key determinant of lineage commitment in PLC and provide a molecular explanation why common liver-damaging risk factors such as alcoholic or non-alcoholic steatohepatitis can lead to either HCC or iCCA. Liver cancer is a major health problem and comprises hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), two frequent and lethal tumour types that differ regarding their morphology, tumour biology, and responses to cancer therapies. We identified the transcription factor and oncogenic master regulator MYC as a switch between HCC and iCCA development. When MYC levels are high at the time point when a hepatocyte becomes a tumour cell, an HCC is growing out. Conversely, if MYC levels are low at this time point, the result is the outgrowth of an iCCA. Our study provides a molecular explanation why common liver-damaging risk factors such as alcoholic or non-alcoholic steatohepatitis can lead to either HCC or iCCA. Furthermore, our data harbour potential for the development of better PLC therapies.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Primary liver cancer (PLC) comprises hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), two frequent and lethal tumour types that differ regarding their tumour biology and responses to cancer therapies. Liver cells harbour a high degree of cellular plasticity and can give rise to either HCC or iCCA. However, little is known about the cell-intrinsic mechanisms directing an oncogenically transformed liver cell to either HCC or iCCA. The scope of this study was to identify cell-intrinsic factors determining lineage commitment in PLC.
METHODS
METHODS
Cross-species transcriptomic and epigenetic profiling was applied to murine HCCs and iCCAs and to two human PLC cohorts. Integrative data analysis comprised epigenetic Landscape In Silico deletion Analysis (LISA) of transcriptomic data and Hypergeometric Optimization of Motif EnRichment (HOMER) analysis of chromatin accessibility data. Identified candidate genes were subjected to functional genetic testing in non-germline genetically engineered PLC mouse models (shRNAmir knockdown or overexpression of full-length cDNAs).
RESULTS
RESULTS
Integrative bioinformatic analyses of transcriptomic and epigenetic data pinpointed the Forkhead-family transcription factors FOXA1 and FOXA2 as MYC-dependent determination factors of the HCC lineage. Conversely, the ETS family transcription factor ETS1 was identified as a determinant of the iCCA lineage, which was found to be suppressed by MYC during HCC development. Strikingly, shRNA-mediated suppression of FOXA1 and FOXA2 with concomitant ETS1 expression fully switched HCC to iCCA development in PLC mouse models.
CONCLUSIONS
CONCLUSIONS
The herein reported data establish MYC as a key determinant of lineage commitment in PLC and provide a molecular explanation why common liver-damaging risk factors such as alcoholic or non-alcoholic steatohepatitis can lead to either HCC or iCCA.
IMPACT AND IMPLICATIONS
UNASSIGNED
Liver cancer is a major health problem and comprises hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA), two frequent and lethal tumour types that differ regarding their morphology, tumour biology, and responses to cancer therapies. We identified the transcription factor and oncogenic master regulator MYC as a switch between HCC and iCCA development. When MYC levels are high at the time point when a hepatocyte becomes a tumour cell, an HCC is growing out. Conversely, if MYC levels are low at this time point, the result is the outgrowth of an iCCA. Our study provides a molecular explanation why common liver-damaging risk factors such as alcoholic or non-alcoholic steatohepatitis can lead to either HCC or iCCA. Furthermore, our data harbour potential for the development of better PLC therapies.
Identifiants
pubmed: 36906109
pii: S0168-8278(23)00175-7
doi: 10.1016/j.jhep.2023.02.039
pmc: PMC10330789
mid: NIHMS1906212
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Transcription Factors
0
KRAS protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
141-149Subventions
Organisme : Intramural NIH HHS
ID : ZIA BC010313
Pays : United States
Organisme : Intramural NIH HHS
ID : ZIA BC011870
Pays : United States
Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.
Références
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Gastroenterology. 2006 Apr;130(4):1117-28
pubmed: 16618406
Oncotarget. 2015 Apr 30;6(12):10102-15
pubmed: 25826091
Cancer Cell. 2008 Dec 9;14(6):447-57
pubmed: 19061836
Cell Death Dis. 2020 May 4;11(5):313
pubmed: 32366840
Nat Rev Cancer. 2015 Nov;15(11):653-67
pubmed: 26493646
Cancer Cell. 2017 Jul 10;32(1):57-70.e3
pubmed: 28648284
Mol Cell. 2016 Apr 7;62(1):79-91
pubmed: 27058788
Cell. 2010 Mar 5;140(5):744-52
pubmed: 20211142
J Clin Invest. 2009 Jun;119(6):1537-45
pubmed: 19436110
J Hepatol. 2018 May;68(5):959-969
pubmed: 29360550
Cancer Cell. 2013 Jun 10;23(6):784-95
pubmed: 23727022
Nature. 2018 Oct;562(7725):69-75
pubmed: 30209397
Nature. 2005 Jun 16;435(7044):944-7
pubmed: 15959514
Oncogene. 2015 Jul;34(29):3815-25
pubmed: 25263440
Nucleic Acids Res. 2014 Oct 29;42(19):11928-40
pubmed: 25294825
J Clin Invest. 2012 Aug;122(8):2911-5
pubmed: 22797301
Hepatology. 2011 Aug;54(2):655-63
pubmed: 21538442
Nat Commun. 2014 Dec 15;5:5696
pubmed: 25526346
Nat Rev Cancer. 2017 Jun;17(6):337-351
pubmed: 28450705
Hum Pathol. 2006 Sep;37(9):1211-6
pubmed: 16938527
Genes (Basel). 2017 May 13;8(5):
pubmed: 28505071
Oncogene. 2002 Apr 4;21(15):2309-19
pubmed: 11948414
Eur J Cancer. 2010 Apr;46(6):1056-61
pubmed: 20202823
Nature. 2014 Jul 24;511(7510):488-492
pubmed: 25043028
Nat Genet. 2012 May 06;44(6):694-8
pubmed: 22561517
Mol Cell. 2002 Feb;9(2):279-89
pubmed: 11864602
Nature. 1983 Aug 18-24;304(5927):596-602
pubmed: 6308472
Nat Genet. 2013 Dec;45(12):1470-1473
pubmed: 24185509
Cancer Cell. 2019 Jun 10;35(6):823-824
pubmed: 31185207
Genome Biol. 2003;4(10):R69
pubmed: 14519204
J Clin Oncol. 2020 Jan 20;38(3):193-202
pubmed: 31790344
Nature. 2020 Feb;578(7793):82-93
pubmed: 32025007
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Mol Cell. 2010 May 28;38(4):576-89
pubmed: 20513432
Stem Cells. 2012 Jul;30(7):1496-508
pubmed: 22523003
PLoS One. 2012;7(1):e30014
pubmed: 22238690
Nature. 2014 Jul 24;511(7510):483-7
pubmed: 25043018
Hepatology. 2014 Jun;59(6):2397-402
pubmed: 24123296
Chin Clin Oncol. 2016 Oct;5(5):66
pubmed: 27829279
Nat Rev Dis Primers. 2021 Sep 9;7(1):65
pubmed: 34504109
Cancer Res. 2020 Sep 15;80(18):3799-3802
pubmed: 32732221
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
Nat Med. 2014 Oct;20(10):1138-46
pubmed: 25216638
Cancer Cell. 2019 Jun 10;35(6):932-947.e8
pubmed: 31130341
Genome Biol. 2020 Feb 7;21(1):32
pubmed: 32033573
Hepatology. 2011 Jul;54(1):173-84
pubmed: 21488076